Answers are grounded in this paper and cite their sources.
Palbociclib is a first-in-class inhibitor of cyclin-dependent kinases 4 and 6 (CDK4 and CDK6). In some but not all cell types, these proteins regulate the transition from the G1 phase to the S phase of the cell cycle. CDK4 and CDK6 regulate proliferation in some types of epithelial cells, including estrogen-receptor–positive luminal cells.1 In estrogen-receptor–positive breast cancers, estrogen induces CDK4 and CDK6 activity, leading to hyperphosphorylation of RB (the gene encoding retinoblastoma protein) and promotion of cell-cycle traversal; this is the rationale for testing CDK4 and CDK6 inhibitors in estrogen-receptor–positive breast cancer.In this issue of the Journal, Turner and . . .
No takes yet. Share an insight, caveat, or question.
Carey et al. (2015) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: